Are we optimising outcomes in Australia’s framework for the supply of plasma-derived medicines?

Australian governments endorse a policy for the evidence-based supply of plasma derivatives, which are procured from domestically collected plasma and managed through contracts between the National Blood Authority and the collection and fractionation agencies. In Australia, these are the Australian Red Cross and CSL Behring respectively. Historically, these organisations have been granted a sole supplier status by Australian governments and their activities, unlike most arrangements for service provision, have not been subject to the mainstream tender processes for government procurement.